LifeMD, Inc. (formerly Conversion Labs) is a leading telehealth company that is transforming the healthcare landscape with direct-to-patient product and service offerings. LifeMD's telemedicine platform enables virtual access to affordable and convenient medical treatment from licensed providers and, when appropriate, prescription medications and over-the-counter products delivered directly to the patient's home.

Company profile
Ticker
LFMD, LFMDP
Exchange
Website
CEO
Justin Schreiber
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
CONVERSION LABS, INC., Immudyne, Inc.
SEC CIK
Corporate docs
Subsidiaries
WorkSimpli Software, LLC • Conversion Labs PR LLC ...
LFMD stock data
News

LifeMD: Q2 Earnings Insights
11 Aug 22
CORRECTION: LifeMD Q2 Adj. EPS $(0.22) Beats $(0.35) Estimate, Sales $30.46M Miss $31.96M Estimate
11 Aug 22
Earnings Scheduled For August 11, 2022
11 Aug 22
LifeMD's Earnings Outlook
10 Aug 22
LifeMD Announces Continued And Rapid Expansion Of Virtual Primary Care To Over 200 Conditions
19 Jul 22
Press releases
LifeMD, Inc. Reports Second Quarter 2022 Results
11 Aug 22
LifeMD, Inc. to Announce Second Quarter 2022 Financial Results and Host Conference Call on August 11, 2022
27 Jul 22
LifeMD Announces Continued and Rapid Expansion of Virtual Primary Care To over 200 Conditions
19 Jul 22
LifeMD Declares Quarterly Dividend on Series A Cumulative Perpetual Preferred Stock
27 Jun 22
Investment data
Securities sold
Number of investors
Calendar
11 Aug 22
20 Aug 22
31 Dec 22
Financial summary
Quarter (USD) | Jun 22 | Mar 22 | Dec 21 | Sep 21 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 21 | Dec 20 | Dec 19 | Dec 18 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 11.72M | 11.72M | 11.72M | 11.72M | 11.72M | 11.72M |
Cash burn (monthly) | 4.46M | 474.74K | 5.21M | 5.1M | 3.37M | 2.62M |
Cash used (since last report) | 7.51M | 800.27K | 8.79M | 8.59M | 5.67M | 4.42M |
Cash remaining | 4.21M | 10.92M | 2.93M | 3.13M | 6.04M | 7.3M |
Runway (months of cash) | 0.9 | 23.0 | 0.6 | 0.6 | 1.8 | 2.8 |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
18 May 22 | Naveen Bhatia | Common Stock | Buy | Acquire P | No | No | 2.136 | 50,000 | 106.8K | 246,349 |
14 Mar 22 | Eric Harold Yecies | Common Stock | Buy | Acquire P | No | No | 3.14 | 5,000 | 15.7K | 51,000 |
10 Mar 22 | Joseph DiTrolio | Common Stock, par value $0.01 | Buy | Acquire P | No | No | 3.28 | 2,000 | 6.56K | 24,500 |
11 Feb 22 | Schreiber Justin | Common Stock | Gift | Dispose G | Yes | No | 0 | 60,000 | 0 | 2,794,620 |
11 Feb 22 | Nicholas P Alvarez | Common Stock | Gift | Acquire G | No | No | 0 | 60,000 | 0 | 169,288 |
Institutional ownership, Q1 2022
26.2% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 46 |
Opened positions | 3 |
Closed positions | 10 |
Increased positions | 14 |
Reduced positions | 14 |
13F shares | Current |
---|---|
Total value | 31.57M |
Total shares | 8.09M |
Total puts | 80.5K |
Total calls | 77.1K |
Total put/call ratio | 1.0 |
Largest owners | Shares | Value |
---|---|---|
Stefan Galluppi | 1.65M | $0 |
Integrated Core Strategies | 1.27M | $12.35M |
RILY B. Riley Financial | 1.2M | $4.24M |
Vanguard | 809.94K | $2.86M |
BLK Blackrock | 425.62K | $1.5M |
AFG American Financial | 340K | $1.2M |
Granahan Investment Management | 295.75K | $1.04M |
Two Sigma Advisers | 271.9K | $960K |
Geode Capital Management | 189.45K | $668K |
Barry Investment Advisors | 178.47K | $630K |
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Avg
|
New words:
amenable, assumption, Counsel, decline, doubt, Eric, forward, frequently, fuel, GC, hurt, inflation, lose, meantime, mediate, mediation, moving, prejudice, rendered, stay, uncertainty
Removed:
achieve, assist, assure, Axle, blood, burn, conclusion, continuing, curtail, CVLBPR, enable, establishing, exceeded, expanding, facilitate, furnish, grouped, improvement, ineligible, install, largely, lead, level, lowest, met, MP, nontransferable, nursing, practice, provision, qualify, revocable, scheduling, sum, therewith
Financial reports
Current reports
8-K
Departure of Directors or Certain Officers
22 Jun 22
8-K
Entry into a Material Definitive Agreement
22 Feb 22
8-K
Regulation FD Disclosure
22 Feb 22
8-K
Departure of Directors or Certain Officers
7 Feb 22
8-K
Departure of Directors or Certain Officers
2 Feb 22
8-K
Regulation FD Disclosure
19 Jan 22
8-K
LifeMD Provides Initial FY2022 Guidance and Announces Preliminary
19 Jan 22
8-K
LifeMD Expands Patient Offerings by Acquiring
12 Jan 22
8-K
Departure of Directors or Certain Officers
12 Nov 21
8-K
LifeMD Announces Launch of Public Offering of Common Stock
4 Oct 21
Registration and prospectus
424B3
Prospectus supplement
17 Aug 22
424B3
Prospectus supplement
17 Aug 22
POS AM
Prospectus update (post-effective amendment)
1 Jul 22
POS AM
Prospectus update (post-effective amendment)
28 Mar 22
8-A12B
Registration of securities on exchange
4 Oct 21
424B5
Prospectus supplement for primary offering
1 Oct 21
424B5
Prospectus supplement for primary offering
30 Sep 21
FWP
Free writing prospectus
29 Sep 21
424B5
Prospectus supplement for primary offering
28 Sep 21
424B5
Prospectus supplement for primary offering
28 Sep 21
Other
EFFECT
Notice of effectiveness
8 Jul 22
EFFECT
Notice of effectiveness
3 May 22
CERT
Certification of approval for exchange listing
4 Oct 21
EFFECT
Notice of effectiveness
3 Aug 21
CORRESP
Correspondence with SEC
29 Jul 21
UPLOAD
Letter from SEC
28 Jul 21
EFFECT
Notice of effectiveness
23 Jun 21
CORRESP
Correspondence with SEC
16 Jun 21
UPLOAD
Letter from SEC
14 Jun 21
EFFECT
Notice of effectiveness
25 May 21
Ownership
4
LifeMD / NAVEEN BHATIA ownership change
19 May 22
4
LifeMD / Eric Harold Yecies ownership change
15 Mar 22
4
LifeMD / Joseph DiTrolio ownership change
11 Mar 22
4
LifeMD / Nicholas P Alvarez ownership change
4 Mar 22
4
LifeMD / Justin Schreiber ownership change
4 Mar 22
4
LifeMD / Alexander Mironov ownership change
14 Feb 22
5
LifeMD / Alexander Mironov ownership change
14 Feb 22
5
LifeMD / Justin Schreiber ownership change
14 Feb 22
4
LifeMD / MARIA E. STAN ownership change
8 Feb 22
3
LifeMD / MARIA E. STAN ownership change
8 Feb 22
Transcripts
2022 Q2
Earnings call transcript
11 Aug 22
2022 Q1
Earnings call transcript
13 May 22
2021 Q4
Earnings call transcript
8 Mar 22
2021 Q3
Earnings call transcript
11 Nov 21
2021 Q2
Earnings call transcript
13 Aug 21
2021 Q1
Earnings call transcript
14 May 21
2020 Q4
Earnings call transcript
30 Mar 21
2020 Q3
Earnings call transcript
16 Nov 20
2020 Q2
Earnings call transcript
17 Aug 20
Reddit threads
Daily Discussion Thread - August 11th, 2022
11 Aug 22
Daily Discussion Thread - August 10th, 2022
10 Aug 22
LifeMD, Inc. (NASDAQ:LFMD) insiders placed bullish bets worth US$2.3m in the last 12 months
15 May 22
Daily Discussion Thread - May 13th, 2022
13 May 22
Daily Discussion Thread - May 12th, 2022
12 May 22
You gave me 3 Micro/Small Caps to look up. Here they are. Give me a few more!
22 Mar 22
Daily Discussion Thread - March 7th, 2022
7 Mar 22
Most anticipated earnings releases for the week beginning March 7th 2022
5 Mar 22
Most Anticipated Earnings Releases for the week beginning March 7th, 2022
5 Mar 22
Daily Discussion Thread - March 4th, 2022
4 Mar 22